Log in

TherapeuticsMD (NASDAQ:TXMD) Cut to Sell at Zacks Investment Research

Last updated on Saturday, August 1st, 2020 by MarketBeat

TherapeuticsMD (NASDAQ:TXMD) was downgraded by Zacks Investment Research from a "hold" rating to a "sell" rating in a report issued on Saturday, Zacks.com reports.

According to Zacks, "TherapeuticsMD, Inc. is a specialty pharmaceutical company focused on creating branded prescription, generic prescription and over-the-counter products targeted exclusively for women. It is developing three advanced hormone replacement products designed to alleviate the symptoms of and reduce the health risks resulting from menopause-related hormone deficiencies. TherapeuticsMD, Inc. is based in Boca Raton, Florida. "

A number of other equities research analysts also recently weighed in on the company. HC Wainwright reaffirmed a "buy" rating and set a $5.00 price objective (down previously from $6.00) on shares of TherapeuticsMD in a research report on Thursday, May 7th. Noble Financial reaffirmed a "buy" rating and set a $10.00 price objective on shares of TherapeuticsMD in a research report on Wednesday, July 22nd. JPMorgan Chase & Co. downgraded TherapeuticsMD from an "overweight" rating to a "neutral" rating in a research report on Tuesday, May 19th. Stifel Nicolaus raised their price objective on TherapeuticsMD from $14.00 to $15.00 and gave the company a "buy" rating in a research report on Thursday, April 16th. Finally, BidaskClub raised TherapeuticsMD from a "sell" rating to a "hold" rating in a research report on Saturday, July 18th. One research analyst has rated the stock with a sell rating, three have given a hold rating and six have issued a buy rating to the company's stock. TherapeuticsMD currently has an average rating of "Buy" and a consensus price target of $8.32.

Shares of TherapeuticsMD stock traded down $0.10 during trading on Friday, hitting $1.85. 5,438,929 shares of the stock traded hands, compared to its average volume of 5,492,363. The firm has a market cap of $502.61 million, a P/E ratio of -2.43 and a beta of 2.16. The company has a current ratio of 3.44, a quick ratio of 3.20 and a debt-to-equity ratio of 22.15. TherapeuticsMD has a 52-week low of $0.85 and a 52-week high of $4.32. The stock's fifty day simple moving average is $1.52 and its 200 day simple moving average is $1.56.

TherapeuticsMD (NASDAQ:TXMD) last issued its quarterly earnings data on Wednesday, May 6th. The company reported ($0.21) earnings per share for the quarter, missing analysts' consensus estimates of ($0.19) by ($0.02). TherapeuticsMD had a negative net margin of 333.88% and a negative return on equity of 1,170.63%. The company had revenue of $12.25 million for the quarter, compared to the consensus estimate of $11.48 million. As a group, equities analysts expect that TherapeuticsMD will post -0.6 EPS for the current year.

In other TherapeuticsMD news, CEO Robert G. Finizio purchased 30,000 shares of the stock in a transaction on Friday, June 5th. The stock was acquired at an average price of $1.15 per share, with a total value of $34,500.00. Following the completion of the acquisition, the chief executive officer now owns 18,335,964 shares in the company, valued at $21,086,358.60. The acquisition was disclosed in a filing with the SEC, which is available at this link. 13.76% of the stock is currently owned by company insiders.

Several institutional investors have recently added to or reduced their stakes in TXMD. ETRADE Capital Management LLC acquired a new stake in shares of TherapeuticsMD during the first quarter worth about $27,000. Wedbush Securities Inc. acquired a new stake in shares of TherapeuticsMD during the second quarter worth about $30,000. IPG Investment Advisors LLC lifted its holdings in shares of TherapeuticsMD by 48.5% during the first quarter. IPG Investment Advisors LLC now owns 30,605 shares of the company's stock worth $32,000 after purchasing an additional 10,000 shares during the period. MBM Wealth Consultants LLC acquired a new stake in shares of TherapeuticsMD during the first quarter worth about $32,000. Finally, Public Employees Retirement Association of Colorado lifted its holdings in shares of TherapeuticsMD by 18.7% during the first quarter. Public Employees Retirement Association of Colorado now owns 48,054 shares of the company's stock worth $51,000 after purchasing an additional 7,554 shares during the period. 67.02% of the stock is owned by hedge funds and other institutional investors.

TherapeuticsMD Company Profile

TherapeuticsMD, Inc operates as a women's healthcare company in the United States. The company offers IMVEXXY for the treatment of moderate-to-severe dyspareunia; BIJUVA, a bio-identical hormone therapy combination of 17ß-estradiol and progesterone for the treatment of moderate-to-severe vasomotor symptoms; and ANNOVERA, a ring-shaped contraceptive vaginal system.

Featured Article: New Google Finance Tool and Screening Stocks

Get a free copy of the Zacks research report on TherapeuticsMD (TXMD)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Analyst Recommendations for TherapeuticsMD (NASDAQ:TXMD)

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to [email protected]

5 Oil Stocks That May Not Survive the Current Crisis

What would you think of the long-term prospects of a business that paid you to buy their products? That’s an oversimplification of what occurred to the May futures contract for oil on April 20. The price for that contract sold for a negative price for the first time in history.

The crisis befalling the oil companies at this time can best be described as “only the strongest survive.” There’s just no way the oil companies can possibly handle month after month of rock-bottom oil prices.

The problem is almost comically simple to understand. There is a massively reduced demand for oil as millions of Americans are following mitigation orders ranging from social distancing guidelines to more restrictive shelter in place orders. At the same time, the market is trying to absorb the oversupply of oil that came from Russia and Saudi Arabia.

However, when the year started, things looked like it might be business as usual for oil producers. The U.S. economy was humming along and there was talk that the second half of the year might finally bring the boost to oil prices that many companies badly needed.

However, since the middle of February, the bottom has dropped out of the market in general, and oil prices have been one of the main sectors to feel the impact.

Initially, investors tried to remain optimistic. A month ago, investors thought that the economy might be reopening sooner rather than later. However, the exact timing of the reopening is about as fluid as a barrel of oil. And with it looking more likely that there will be more demand destruction at least through May, there’s very little to prop up the stock of any oil companies.

And that means that, in all likelihood, there will not be room left for some oil companies. We’ve highlighted five oil stocks that have a strong probability of not surviving the chaos surrounding the coronavirus and our nation’s response.

View the "5 Oil Stocks That May Not Survive the Current Crisis".

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.